Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 10:05:22 06/02/2026 pm IST			5-day change	1st Jan Change
2,198.00 ^GBX	+0.83%		+18.68%	+20.47%

10:33pm	European Stocks Track Higher in Friday Trading; Stellantis Tanks on $26.5 Billion Write-Down	MT
09:49pm	GSK Chair Jonathan Symonds buys GBP53,000 in shares	AN

Press Releases

05/02	GSK : FY 2025 results transcript	PU
04/02	Glaxo: Q4 Earnings Snapshot	AQ
04/02	GSK : Full results	PU
04/02	GSK : FY 2025 results slides	PU
04/02	GSK : FY 2025 pipeline assets and clinical trials report	PU
04/02	GSK : FY 2025 results infographic	PU
04/02	GSK : FY 2025 US dollar translation	PU
04/02	GSK : delivers strong 2025 performance and re-affirms long-term outlooks	PU
26/01	GSK : RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older	PU
23/01	GSK : Trelegy Ellipta approved in China for use in adults with uncontrolled asthma	PU
21/01	GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026	BU
21/01	GSK enters agreement to acquire RAPT Therapeutics	AQ
20/01	GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million	BU
20/01	GSK : Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding	PU
14/01	GSK : Q4 2025 pre announcement aide memoire	PU
07/01	GSK : Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission	PU
07/01	GSK : announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B	PU
20/12	GSK : enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans	PU
19/12	GSK : CBCR data 2024	PU
17/12	GSK plc - Exdensur approved by US FDA for the treatment of severe asthma	AQ
17/12	Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma	BU
17/12	GSK : Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma	PU
16/12	GSK : Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps	PU
11/12	GSK'227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA	AQ
01/12	GSK : data at ASH show potential to redefine outcomes for people living with blood cancers	PU